Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024
Aspirin Metabolites and Mammographic Breast Density in Premenopausal Women.
СтатьяПоддержка NIH: внешняя программаНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Singh Ramkrishna K, Getz Kayla R, Kyeyune Joy K, Jeon Myung S, Luo Chongliang, Luo Jingqin, Toriola Adetunji T
Аннотация
BACKGROUND: Studies investigating the associations of self-reported aspirin use and mammographic breast density (MBD) have reported conflicting results. Therefore, we investigated the associations of aspirin metabolites with MBD in premenopausal women.
METHODS: We performed this study on 705 premenopausal women who had a fasting blood draw for metabolomic profiling. We performed covariate-adjusted linear regression models to calculate the least square means of volumetric measures of MBD [volumetric percent density (VPD), dense volume (DV), and nondense volume (NDV)] by quartiles of aspirin metabolites [salicyluric glucuronide, 2-hydroxyhippurate (salicylurate), salicylate, and 2,6-dihydroxybenzoic acid].
RESULTS: Approximately 13% of participants reported taking aspirin in the past 12 months. Aspirin users had higher levels of 2-hydroxyhippurate (salicylurate), salicylate, and salicyluric glucuronide (peak area) than nonusers, but only the mean peak area of salicyluric glucuronide was increased by both dose (1-2 tablets per day = 1,140,663.7 and ≥3 tablets per day = 1,380,476.0) and frequency (days per week: 1 day = 888,129.3, 2-3 days = 1,199,897.9, and ≥4 days = 1,654,637.0). Aspirin metabolites were not monotonically associated with VPD, DV, or NDV.
CONCLUSIONS: Given the null results, additional research investigating the associations of aspirin metabolites in breast tissue and MBD is necessary. Impact: Elucidating the determinants of MBD, a strong risk factor for breast cancer, can play an important role in breast cancer prevention. Future studies should determine the associations of nonaspirin NSAID metabolites with MBD.
METHODS: We performed this study on 705 premenopausal women who had a fasting blood draw for metabolomic profiling. We performed covariate-adjusted linear regression models to calculate the least square means of volumetric measures of MBD [volumetric percent density (VPD), dense volume (DV), and nondense volume (NDV)] by quartiles of aspirin metabolites [salicyluric glucuronide, 2-hydroxyhippurate (salicylurate), salicylate, and 2,6-dihydroxybenzoic acid].
RESULTS: Approximately 13% of participants reported taking aspirin in the past 12 months. Aspirin users had higher levels of 2-hydroxyhippurate (salicylurate), salicylate, and salicyluric glucuronide (peak area) than nonusers, but only the mean peak area of salicyluric glucuronide was increased by both dose (1-2 tablets per day = 1,140,663.7 and ≥3 tablets per day = 1,380,476.0) and frequency (days per week: 1 day = 888,129.3, 2-3 days = 1,199,897.9, and ≥4 days = 1,654,637.0). Aspirin metabolites were not monotonically associated with VPD, DV, or NDV.
CONCLUSIONS: Given the null results, additional research investigating the associations of aspirin metabolites in breast tissue and MBD is necessary. Impact: Elucidating the determinants of MBD, a strong risk factor for breast cancer, can play an important role in breast cancer prevention. Future studies should determine the associations of nonaspirin NSAID metabolites with MBD.